FURADANTIN (nitrofurantoin) by Aurobindo Pharma is clinical pharmacology each nitrofurantoin capsule (monohydrate/macrocrystals) contains two forms of nitrofurantoin. First approved in 1953.
Drug data last refreshed 1h ago · AI intelligence enriched 4h ago
FURADANTIN (nitrofurantoin) is an oral small-molecule antibiotic used to treat uncomplicated urinary tract infections (UTIs). It works by inhibiting bacterial DNA synthesis and is highly concentrated in urine. The drug combines macrocrystalline and monohydrate formulations to optimize bioavailability and sustained release.
Product is approaching loss of exclusivity with moderate competitive pressure (30% intensity), signaling contraction of brand team headcount and shift toward generic support.
CLINICAL PHARMACOLOGY Each nitrofurantoin capsule (monohydrate/macrocrystals) contains two forms of nitrofurantoin. Twenty-five percent is macrocrystalline nitrofurantoin, which has slower dissolution and absorption than nitrofurantoin monohydrate. The remaining 75% is nitrofurantoin monohydrate…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Gag Therapy for Recurrent Urinary Tract Infection Assessing Comparability to International Nitrofurantoin Gold Standard Study
Comparative Study to Evaluate Efficacy and Safety of Gepotidacin to Nitrofurantoin in Treatment of Uncomplicated Urinary Tract Infection (UTI)
Oral Omadacycline vs. Oral Nitrofurantoin for the Treatment of Cystitis
Food Study of Nitrofurantoin Macrocrystals 100 mg Capsules and Macrodantin® 100 mg
Food Study of Nitrofurantoin Monohydrate/Macrocrystals Capsules 100 mg and Macrobid® Capsules 100 mg
Worked on FURADANTIN at Aurobindo Pharma? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on FURADANTIN in a LOE-approaching stage offers limited career growth in brand-building but strong opportunities in generic optimization, payer contracting, and lifecycle management. Professionals on this team are likely managing decline, cost efficiency, and transition to post-exclusivity models rather than driving expansion.